Yes, you may travel with Calan SR, but keep the medication in its original packaging with the prescription label visible. In the UK, it is classified as a prescription-only medicine, so you should carry a copy of the prescription or a doctor’s letter, especially when traveling to countries with strict drug-import regulations.
Verapamil is not a controlled substance and is not screened for in standard workplace or anti-doping tests. However, if a full medication list is requested, you should disclose its use to avoid any misunderstandings.
Calan SR capsules are opaque, typically orange-coloured for the 120 mg strength and blue-coloured for the 240 mg strength. Imprint codes vary by batch; the exact markings can be verified using the MHRA’s online medicines database.
Switching is possible but should be done under medical supervision because the extended-release formulation provides different plasma concentration profiles. Your doctor will calculate an equivalent dose and monitor for adverse effects during the transition.
Low-dose aspirin does not interfere with verapamil’s action and is commonly co-prescribed for cardiovascular protection. Nonetheless, always inform your prescriber of all concurrent medicines.
Keep the bottles in a cool, dry place away from direct sunlight. If ambient temperature frequently exceeds 30 °C, store the medication in a refrigerator (2-8 °C) but allow it to reach room temperature before swallowing.
Taking Calan SR with a meal improves tolerability and does not significantly alter its overall absorption. It is recommended to ingest the capsule with food to reduce the risk of gastrointestinal upset.
If the missed dose is less than 6 hours before the next scheduled dose, take it as soon as you remember. If more than 6 hours have passed, skip the missed dose and continue with your regular dosing schedule. Do not double-dose to “catch up.”
When a prescription is written, the NHS may provide the medication at a standard prescription charge, or it may be exempt for certain groups (e.g., under-16s, over-60s, low-income patients). Discuss any concerns about affordability with your GP or pharmacist.
Verapamil can cause dizziness or slowed heart rate, which may affect performance. Pilots and operators of heavy machinery should inform their occupational health provider; they may be required to undergo periodic medical assessment before continuing work.
Calan SR (verapamil) is a prescription-only medication in the United Kingdom, classified as a non-dihydropyridine calcium-channel blocker. It is supplied as an extended-release (SR = sustained release) pill in strengths of 120 mg and 240 mg. The drug is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of hypertension, chronic stable angina, and certain cardiac arrhythmias.
Verapamil blocks L-type calcium channels in cardiac and smooth-muscle cells. By reducing calcium entry, it:
Because verapamil is released slowly from the SR formulation, plasma concentrations rise gradually, providing once-daily dosing for many patients while minimizing peaks that can cause pronounced hypotension or bradycardia.
Hypertension - Verapamil lowers systolic and diastolic blood pressure by arterial vasodilation and reduced cardiac output.
Chronic Stable Angina - By decreasing myocardial oxygen consumption and improving coronary blood flow, it relieves chest pain during exertion.
Cardiac Arrhythmias - Effective for rate control in atrial fibrillation/flutter and for terminating or preventing supraventricular tachycardia through AV-node slowing.
These uses are endorsed by MHRA labeling and supported by NICE technology appraisal guidance for calcium-channel blockers in hypertension and angina.
Off-label use requires medical supervision and individualized risk assessment.
Ideal candidates
Absolute contraindications
Relative contraindications
Patients should provide a complete medication, supplement, and herbal list to their prescriber before starting Calan SR.
Formulation: Extended-release capsules, to be swallowed whole; do not crush, chew, or split.
Standard dosing:
Hypertension: Start with one 240 mg capsule once daily; may increase to two capsules (480 mg) once daily based on response and tolerability.
Angina: Begin with one 120 mg capsule once daily; increase gradual to a maximum of two 240 mg capsules (480 mg) per day as needed.
Arrhythmia rate control: Often 240 mg twice daily (total 480 mg per day), but dosing should be individualised by the cardiologist.
Special populations:
Renal impairment (CrCl < 30 mL/min): Consider starting at 120 mg once daily and titrating slowly.
Hepatic impairment: Reduce initial dose by 50 % and monitor liver function.
Elderly: Begin with the lowest effective dose (120 mg) and increase cautiously.
Missed dose: Take the missed dose as soon as remembered only if at least 6 hours remain before the next scheduled dose; otherwise skip and resume normal schedule. Do not double the dose.
Overdose: Symptoms may include severe hypotension, bradycardia, AV block, and cardiac arrest. Seek emergency medical care; treatment is supportive, with intravenous calcium or vasopressors as needed.
Discontinuation: Abrupt cessation can lead to rebound hypertension or angina. Taper the dose over 1-2 weeks under medical supervision.
Patients should contact their healthcare provider promptly if they experience dizziness, fainting, new swelling, or shortness of breath.
This article provides educational information about Calan SR (verapamil) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
